

BIBLIOGRAPHY

- Aalto-Setälä, K., Koivisto, U. M., Miettinen, T. A., Gylling, H., Kesäniemi, Y. A., Savolainen, M., et al. (1992). Prevalence and geographical distribution of major LDL receptor gene rearrangements in Finland. *J Intern Med*, 231(3), 227-234.
- Abifadel, M., Varret, M., Rabes, J. P., Allard, D., Ouguerram, K., Devillers, M., et al. (2003). Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. *Nat Genet*, 34(2), 154-156.
- Alberts, A. W., Chen, J., Kuron, G., Hunt, V., Huff, J., Hoffman, C., et al. (1980). Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. *Proc Natl Acad Sci U S A*, 77(7), 3957-3961.
- Alberts, B., Bray, D., Lewis, J., Raff, M., Roberts, K., & Watson, J. D. (1994). *Molecular biology of the cell*. 3rd edition. New York: Garland Publishing.
- Allen, J. M., Thompson, G. R., Myant, N. B., Steiner, R., & Oakley, C. M. (1980). Cardiovascular complications of homozygous familial hypercholesterolaemia. *Br Heart J*, 44(4), 361-368.
- Alonso, R., Defesche, J. C., Tejedor, D., Castillo, S., Stef, M., Mata, N., et al. (2009). Genetic diagnosis of familial hypercholesterolemia using a DNA-array based platform. *Clin Biochem*, 42(9), 899-903.
- Anderson, K. M., Castelli, W. P., & Levy, D. (1987). Cholesterol and mortality. 30 years of follow-up from the Framingham study. *JAMA*, 257(16), 2176-2180.
- Anderson, R. G., Brown, M. S., & Goldstein, J. L. (1977). Role of the coated endocytic vesicle in the uptake of receptor-bound low density lipoprotein in human fibroblasts. *Cell*, 10(3), 351-364.
- Andrulis, I. L., Anton-Culver, H., Beck, J., Bove, B., Boyd, J., Buys, S., et al. (2002). Comparison of DNA- and RNA-based methods for detection of truncating BRCA1 mutations. *Hum Mutat*, 20(1), 65-73.
- Austin, M. A., Hutter, C. M., Zimmern, R. L., & Humpries, S. E. (2004a). Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. *Am J Epidemiol*, 160, 407-420.
- Austin, M. A., Hutter, C. M., Zimmern, R. L., & Humpries, S. E. (2004b). Familial hypercholesterolaemia and coronary heart disease: a HuGE association review. *Am J Epidemiol*, 160, 421-429.
- Ayyobi, A. F., Zambon, A., & Brunzell, J. D. (2007). Premature coronary artery disease and apolipoprotein B and apolipoprotein A-I. *Int Congr Ser*, 1303, 85-94.
- Azian, M., Hapizah, M. N., Khalid, B. A., Khalid, Y., Rosli, A., & Jamal, R. (2006). Use of the denaturing gradient gel electrophoresis (DGGE) method for

mutational screening of patients with familial hypercholesterolaemia (FH) and Familial defective apolipoprotein B100 (FDB). *Malays J Pathol*, 28(1), 7-15.

- Bambauer, R. (2002). Low-density lipoprotein apheresis: clinical results with different methods. *Artif Organs*, 26(2), 133-139.
- Baron, H., Fung, S., Aydin, A., Bahring, S., Luft, F. C., & Schuster, H. (1996). Oligonucleotide ligation assay (OLA) for the diagnosis of familial hypercholesterolemia. *Nat Biotechnol*, 14(10), 1279-1282.
- Barres, B. A., & Smith, S. J. (2001). Neurobiology. Cholesterol--making or breaking the synapse. *Science*, 294(5545), 1296-1297.
- Barter, P. J. (2002). Coronary plaque regression: role of low density lipoprotein-apheresis. *J Am Coll Cardiol*, 40(2), 228-230.
- Beaumont, V., Jacotot, B., & Beaumont, J. L. (1976). Ischaemic disease in men and women with familial hypercholesterolaemia and xanthomatosis: a comparative study of genetic and environmental factors in 274 heterozygous cases. *Atherosclerosis*, 24(3), 441-450.
- Betard, C., Kessling, A. M., Roy, M., Chamberland, A., Lussier-Cacan, S., & Davignon, J. (1992). Molecular genetic evidence for a founder effect in familial hypercholesterolemia among French Canadians. *Hum Genet*, 88(5), 529-536.
- Bhatnagar, D., Soran, H., & Durrington, P. N. (2008). Hypercholesterolaemia and its management. *BMJ*, 337, a993.
- Black, H. R. (1992). Cardiovascular risk factors. In Zaret, B. L., Moser, M., and Cohen, L. S. *Yale University School of Medicine heart book*. New York: Heart Books.
- Blesa, S., Garcia-Garcia, A. B., Martinez-Hervas, S., Mansego, M. L., Gonzalez-Albert, V., Ascaso, J. F., et al. (2006). Analysis of sequence variations in the LDL receptor gene in Spain: general gene screening or search for specific alterations? *Clin Chem*, 52(6), 1021-1025.
- Bodamer, O. A., Bercovich, D., Schlabach, M., Ballantyne, C., Zoch, D., & Beaudet, A. L. (2002). Use of denaturing HPLC to provide efficient detection of mutations causing familial hypercholesterolemia. *Clin Chem*, 48(11), 1913-1918.
- Bouillon, R., Okamura, W. H., & Norman, A. W. (1995). Structure-function relationships in the vitamin D endocrine system. *Endocr Rev*, 16(2), 200-257.
- Brenner, S., Johnson, M., Bridgham, J., Golda, G., Lloyd, D. H., Johnson, D., et al. (2000). Gene expression analysis by massively parallel signature sequencing (MPSS) on microbead arrays. *Nat Biotechnol*, 18(6), 630-634.

- Breton, J., Sichel, F., Abbas, A., Marnay, J., Arsene, D., & Lechevrel, M. (2003). Simultaneous use of DGGE and DHPLC to screen TP53 mutations in cancers of the esophagus and cardia from a European high incidence area (Lower Normandy, France). *Mutagenesis*, *18*(3), 299-306.
- Brightwell, G., Wycherley, R., Potts, G., & Waghorn, A. (2002). A high-density SNP map for the FRAX region of the X chromosome. Single-nucleotide polymorphisms. *J Hum Genet*, *47*(11), 567-575.
- Brown, M. S., & Goldstein, J. L. (1976a). Receptor-mediated control of cholesterol metabolism. *Science*, *191*(4223), 150-154.
- Brown, M. S., & Goldstein, J. L. (1976b). Familial hypercholesterolemia: A genetic defect in the low-density lipoprotein receptor. *N Engl J Med*, *294*(25), 1386-1390.
- Brown, M. S., & Goldstein, J. L. (1986). A receptor-mediated pathway for cholesterol homeostasis. *Science*, *232*, 34-47.
- Brown, M. S., & Goldstein, J. L. (2009). Cholesterol feedback: from Schoenheimer's bottle to Scap's MELADL. *J Lipid Res*, *50* Suppl, S15-27.
- Brown, M. S., Anderson, R. G., & Goldstein, J. L. (1977). Mutations affecting the binding, internalization, and lysosomal hydrolysis of low density lipoprotein in cultured human fibroblasts, lymphocytes, and aortic smooth muscle cells. *J Supramol Struct*, *6*(1), 85-94.
- Brown, M. S., Anderson, R. G., & Goldstein, J. L. (1983). Recycling receptors: the round-trip itinerary of migrant membrane proteins. *Cell*, *32*(3), 663-667.
- Brown, M. S., Anderson, R. G., & Goldstein, J. L. (1983). Recycling receptors: the round-trip itinerary of migrant membrane proteins. *Cell*, *32*(3), 663-667.
- Brown, M. S., Herz, J., & Goldstein, J. L. (1997). LDL-receptor structure. Calcium cages, acid baths and recycling receptors. *Nature*, *388*(6643), 629-630.
- Bunn, C. F., Lintott, C. J., Scott, R. S., & George, P. M. (2002). Comparison of SSCP and DHPLC for the detection of LDLR mutations in a New Zealand cohort. *Hum Mutat*, *19*(3), 311.
- Burns, F. S. (1920). A contribution to the study of the etiology of xanthomata. *Arch Derm Syph*, *2*, 415-429.
- Cashin-Hemphill, L., Noone, M., Abbott, J. F., Waksmonski, C. A., & Lees, R. S. (2000). Low-density lipoprotein apheresis therapy during pregnancy. *Am J Cardiol*, *86*(10), 1160, A1110.
- Charlton-Menys, V., & Durrington, P. N. (2008). Human cholesterol metabolism and therapeutic molecules. *Exp Physiol*, *93*(1), 27-42.

- Chen, W. J., Goldstein, J. L., & Brown, M. S. (1990). NPXY, a sequence often found in cytoplasmic tails, is required for coated pit-mediated internalization of the low density lipoprotein receptor. *J Biol Chem*, 265(6), 3116-3123.
- Civeira, F. (2004). Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. *Atherosclerosis*, 173(1), 55-68.
- Cooper, A. D. (1997). Hepatic uptake of chylomicron remnants. *J Lipid Res*, 38(11), 2173-2192.
- Costet, P., Krempf, M., & Cariou, B. (2008). PCSK9 and LDL cholesterol: unravelling the target to design the bullet. *Trends Biochem Sci*, 33(9), 426-434.
- Cotton, R. G. (1993). Current methods of mutation detection. *Mutat Res*, 285(1), 125-144.
- Cotton, R. G. (1997). Slowly but surely towards better scanning for mutations. *Trends Genet*, 13(2), 43-46.
- Cotton, R. G. (2000). Methods in clinical molecular genetics. *Eur J Pediatr*, 159 Suppl 3, S179-182.
- Daniels, T. F., Killinger, K. M., Michal, J. J., Wright, R. W., Jr., & Jiang, Z. (2009). Lipoproteins, cholesterol homeostasis and cardiac health. *Int J Biol Sci*, 5(5), 474-488.
- Davidson, M. H., Maki, K. C., Karp, S. K., & Ingram, K. A. (2002). Management of hypercholesterolaemia in postmenopausal women. *Drugs Aging*, 19(3), 169-178.
- Davis, C. G., Elhammer, A., Russell, D. W., Schneider, W. J., Kornfeld, S., Brown, M. S., et al. (1986). Deletion of clustered O-linked carbohydrates does not impair function of low density lipoprotein receptor in transfected fibroblasts. *J Biol Chem*, 261(6), 2828-2838.
- Davis, C. G., Goldstein, J. L., Sudhof, T. C., Anderson, R. G., Russell, D. W., & Brown, M. S. (1987a). Acid-dependent ligand dissociation and recycling of LDL receptor mediated by growth factor homology region. *Nature*, 326(6115), 760-765.
- Davis, C. G., van Driel, I. R., Russell, D. W., Brown, M. S., & Goldstein, J. L. (1987b). The low density lipoprotein receptor. Identification of amino acids in cytoplasmic domain required for rapid endocytosis. *J Biol Chem*, 262(9), 4075-4082.
- De Castro-Oros, I., Pocovi, M., Civeira, F. (2010). The genetic basis of familial hypercholesterolemia: inheritance, linkages, and mutations. *The Application of Clinical Genetics*, 3,53-64.
- Defesche, J. (2000). Familial Hypercholesterolemia. In: Betteridge, D.J. eds. *Lipids and Vascular Disease*. London: Martin Dunitz Ltd.

- Defesche, J. C. (2004). Low-density lipoprotein receptor--its structure, function, and mutations. *Semin Vasc Med*, 4(1), 5-11.
- Descamps, O. S., Leysen, X., Van Leuven, F., & Heller, F. R. (2001). The use of Achilles tendon ultrasonography for the diagnosis of familial hypercholesterolemia. *Atherosclerosis*, 157(2), 514-518.
- Donohoe, E. (2005). Denaturing high-performance liquid chromatography using the WAVE DNA fragment analysis system. *Methods Mol Med*, 108, 173-187.
- Doris, P. A., Oefner, P. J., Chilton, B. S., & Hayward-Lester, A. (1998). Quantitative analysis of gene expression by ion-pair high-performance liquid chromatography. *J Chromatogr A*, 806(1), 47-60.
- Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., et al. (1998). Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. *JAMA*, 279(20), 1615-1622.
- Durrington, P. (2003). Dyslipidemia. *Lancet*, 362, 717-731.
- Durrington, P. N. (2001). Rigorous detection and vigorous treatment of familial hypercholesterolaemia. *Lancet*, 357(9256), 574-575.
- Durrington, P.N. (2007). *Hyperlipidaemia. Diagnosis and Management*. 3rd Edition. London: Hodder Arnold Publication.
- Durst, R., Jansen, A., Erez, G., Bravdo, R., Butbul, E., Ben Avi, L., Shpitzen, S., Lotan, C., Leitersdorf, E., Defesche, J., Friedlander, Y., Meiner, V., & Miserez, A. R. (2006). The discrete and combined effect of SREBP-2 and SCAP isoforms in the control of plasma lipids among familial hypercholesterolaemia patients. *Atherosclerosis*, 189, 443-450.
- Ellis, L. A., Taylor, C. F., & Taylor, G. R. (2000). A comparison of fluorescent SSCP and denaturing HPLC for high throughput mutation scanning. *Hum Mutat*, 15(6), 556-564.
- Endo, A., Kuroda, M., & Tanzawa, K. (1976a). Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. *FEBS Lett*, 72(2), 323-326.
- Endo, A., Kuroda, M., & Tsujita, Y. (1976b). ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterol synthesis produced by *Penicillium citrinum*. *J Antibiot (Tokyo)*, 29(12), 1346-1348.
- Eng, C., Brody, L. C., Wagner, T. M., Devilee, P., Vijg, J., Szabo, C., et al. (2001). Interpreting epidemiological research: blinded comparison of methods used to estimate the prevalence of inherited mutations in BRCA1. *J Med Genet*, 38(12), 824-83.

- Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). (2001). *JAMA*, 285(19), 2486-2497.
- Franca, L. T., Carrilho, E., & Kist, T. B. (2002). A review of DNA sequencing techniques. *Q Rev Biophys*, 35(2), 169-200.
- Francke, U., Brown, M. S., & Goldstein, J. L. (1984). Assignment of the human gene for the low density lipoprotein receptor to chromosome 19: synteny of a receptor, a ligand, and a genetic disease. *Proc Natl Acad Sci U S A*, 81(9), 2826-2830.
- Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972). Estimation of the concentration of low density lipoprotein cholesterol in plasma without the use of preparative ultracentrifugation. *Clin Chem*, 18, 499-502.
- Frueh, F. W., & Noyer-Weidner, M. (2003). The use of denaturing high-performance liquid chromatography (DHPLC) for the analysis of genetic variations: impact for diagnostics and pharmacogenetics. *Clin Chem Lab Med*, 41(4), 452-461.
- Gagne, C., Gaudet, D., & Bruckert, E. (2002). Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. *Circulation*, 105(21), 2469-2475.
- Gagne, C., Moorjani, S., Brun, D., Toussaint, M., & Lupien, P. J. (1979). Heterozygous familial hypercholesterolemia. Relationship between plasma lipids, lipoproteins, clinical manifestations and ischaemic heart disease in men and women. *Atherosclerosis*, 34(1), 13-24.
- Gent, J., & Braakman, I. (2004). Low-density lipoprotein receptor structure and folding. *Cell Mol Life Sci*, 61(19-20), 2461-2470.
- Girao, H., Mota, C., & Pereira, P. (1999). Cholesterol may act as an antioxidant in lens membranes. *Curr Eye Res*, 18(6), 448-454.
- Goldstein, J. L., & Brown, M. S. (1973). Familial hypercholesterolemia: identification of a defect in the regulation of 3-hydroxyl-3-methylglutarylcoenzyme A reductase activity associated with overproduction of cholesterol. *Proc Nat Acad Sci USA*, 70, 2804-2808.
- Goldstein, J. L., & Brown, M. S. (1974). Binding and degradation of low density lipoproteins by cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia. *J Biol Chem*, 249(16), 5153-5162.
- Goldstein, J. L., & Brown, M. S. (1985). The LDL receptor and the regulation of cellular cholesterol metabolism. *J Cell Sci Suppl*, 3, 131-137.

- Goldstein, J. L., & Brown, M. S. (2009). The LDL receptor. *Arterioscler Thromb Vasc Biol*, 29(4), 431-438.
- Goldstein, J. L., Brown, M. S., Anderson, R. G., Russell, D. W., & Schneider, W. J. (1985). Receptor-mediated endocytosis: concepts emerging from the LDL receptor system. *Annu Rev Cell Biol*, 1, 1-39.
- Goldstein, J. L., Hobbs, H. H., & Brown, M. S. (2001). Familial hypercholesterolemia. In: Scriver, C.R., Sly, W.S., Childs, B., et al, eds. *The metabolic and molecular bases of inherited disease*. New York: McGraw-Hill Companies, Inc.
- Goldstein, J. L., Schrott, H. G, Hazzard, W. R, Bierman, E. L., & Motulsky, A G. (1973). Hyperlipidemia in coronary heart disease II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. *J Clin Invest*, 52, 1544-1568.
- Gordon, B. R., & Saal, S. D. (1996). Current status of low density lipoprotein-apheresis for the therapy of severe hyperlipidemia. *Curr Opin Lipidol*, 7(6), 381-384.
- Grompe, M. (1993). The rapid detection of unknown mutations in nucleic acids. *Nat Genet*, 5(2), 111-117.
- Gross, E., Arnold, N., Goette, J., Schwarz-Boeger, U., & Kiechle, M. (1999). A comparison of BRCA1 mutation analysis by direct sequencing, SSCP and DHPLC. *Hum Genet*, 105(1-2), 72-78.
- Grundey, S. M., & Vega, G. L. (1990). Causes of high blood cholesterol. *Circulation*, 81(2), 412-427.
- Grundey, S. M., Balady, G. J., Criqui, M. H., Fletcher, G., Greenland, P., Hiratzka, L. F., et al. (1998). Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. American Heart Association. *Circulation*, 97(18), 1876-1887.
- Hannachi-M'Zali, F., Ambler, J. E., Taylor, C. F., & Hawkey, P. M. (2002). Examination of single and multiple mutations involved in resistance to quinolones in *Staphylococcus aureus* by a combination of PCR and denaturing high-performance liquid chromatography (DHPLC). *J Antimicrob Chemother*, 50(5), 649-655.
- Harvey, J. F., & Sampson, J. R. (2004). Mutation scanning for the clinical laboratory: DHPLC. *Methods Mol Med*, 92, 45-66.
- Havel, R. J., Hunninghake, D. B., Illingworth, D. R., Lees, R. S., Stein, E. A., Tobert, J. A., et al. (1987). Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. A multicenter study. *Ann Intern Med*, 107(5), 609-615.
- Heath, K. E., Day, I. N., & Humphries, S. E. (2000). Universal primer quantitative fluorescent multiplex (UPQFM) PCR: a method to detect major and minor

- rearrangements of the low density lipoprotein receptor gene. *J Med Genet*, 37(4), 272-280.
- Heath, K. E., Gahan, M., Whittall, R. A., & Humphries, S. E. (2001). Low density lipoprotein receptor gene (LDLR) world-wide website in familial hypercholesterolaemia: update, new features and mutation analysis. *Atherosclerosis*, 154, 243-246.
- Heiberg, A. (1975). The risk of atherosclerosis vascular disease in subjects with xanthomatosis. *Acta Med Scand*, 198(4), 249-261.
- Hendriks, H. F., Weststrate, J. A., van Vliet, T., & Meijer, G. W. (1999). Spreads enriched with three different levels of vegetable oil sterols and the degree of cholesterol lowering in normocholesterolaemic and mildly hypercholesterolaemic subjects. *Eur J Clin Nutr*, 53(4), 319-327.
- Highsmith Jr., W.E. (2005) Electrophoretic methods for mutation detection and DNA sequencing. In Coleman, W. B., & Tsongalis, G. J. *Molecular diagnostics for the clinical laboratories*. 2nd edition. New Jersey: Humana Press Inc.
- Hobbs, H. H., Brown, M. S., & Goldstein, J. L. (1992). Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. *Hum Mutat*, 1(6), 445-466.
- Hobbs, H. H., Russell, D. W., Brown, M. S., & Goldstein, J. L. (1990). The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. *Annu Rev Genet*, 24, 133-170.
- Hoogendoorn, B., Owen, M. J., Oefner, P. J., Williams, N., Austin, J., & O'Donovan, M. C. (1999). Genotyping single nucleotide polymorphisms by primer extension and high performance liquid chromatography. *Hum Genet*, 104(1), 89-93.
- Hopkins, P. N., Stephenson, S., Wu, L. L., Riley, W. A., Xin, Y., & Hunt, S. C. (2001). Evaluation of coronary risk factors in patients with heterozygous familial hypercholesterolemia. *Am J Cardiol*, 87(5), 547-553.
- Huber, C.G., Oefner, P.J., & Boon, G.K. (1995). Rapid and accurate sizing of DNA fragments by ion-pair chromatography on alkylated nonporous poly(styrene-divinylbenzene) particles. *Anal Chem*, 67, 578-585.
- Hudgins, L. C., Gordon, B. R., Parker, T. S., Saal, S. D., Levine, D. M., & Rubin, A. L. (2002). LDL Apheresis: an effective and safe treatment for refractory hypercholesterolemia. *Cardiovasc Drug Rev*, 20(4), 271-280.
- Hume, R., & Boyd, G. S. (1978). Cholesterol metabolism and steroid-hormone production. *Biochem Soc Trans*, 6(5), 893-898.
- Humphries, S. E., Galton, D., & Nicholls, P. (1997a). Genetic testing for familial hypercholesterolaemia: practical and ethical issues. *QJM*, 90(3), 169-181.
- Humphries, S. E., Gudnason, V., Whittall, R., & Day, I. N. (1997b). Single-strand conformation polymorphism analysis with high throughput modifications, and

its use in mutation detection in familial hypercholesterolemia. International Federation of Clinical Chemistry Scientific Division: Committee on Molecular Biology Techniques. *Clin Chem*, 43(3), 427-435.

- Hunt, S. C., Hopkins, P. N., Bulka, K., McDermott, M. T., Thorne, T. L., Wardell, B. B., et al. (2000). Genetic localization to chromosome 1p32 of the third locus for familial hypercholesterolemia in a Utah kindred. *Arterioscler Thromb Vasc Biol*, 20(4), 1089-1093.
- Innerarity, T. L., Mahley, R. W., Weisgraber, K. H., Bersot, T. P., Krauss, R. M., Vega, G. L., et al. (1990). Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia. *J Lipid Res*, 31(8), 1337-1349
- Jensen, J., Blankenhorn, D. H., & Kornerup, V. (1967). Coronary disease in familial hypercholesterolaemia. *Circulation*, 34, 77-82.
- Jin, L., Underhill, P. A., Doctor, V., Davis, R. W., Shen, P., Cavalli-Sforza, L. L., et al. (1999). Distribution of haplotypes from a chromosome 21 region distinguishes multiple prehistoric human migrations. *Proc Natl Acad Sci U S A*, 96(7), 3796-3800.
- Jones, A. C., Austin, J., Hansen, N., Hoogendoorn, B., Oefner, P. J., Cheadle, J. P., et al. (1999a). Optimal temperature selection for mutation detection by denaturing HPLC and comparison to single-stranded conformation polymorphism and heteroduplex analysis. *Clin Chem*, 45(8 Pt 1), 1133-1140.
- Jones, A. C., Sampson, J. R., & Cheadle, J. P. (2001). Low level mosaicism detectable by DHPLC but not by direct sequencing. *Hum Mutat*, 17(3), 233-234.
- Jones, A. C., Shyamsundar, M. M., Thomas, M. W., Maynard, J., Idziaszczyk, S., Tomkins, S., et al. (1999b). Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis. *Am J Hum Genet*, 64(5), 1305-1315.
- Junyent, M., Gilabert, R., Zambon, D., Nunez, I., Vela, M., Civeira, F., et al. (2005). The use of Achilles tendon sonography to distinguish familial hypercholesterolemia from other genetic dyslipidemias. *Arterioscler Thromb Vasc Biol*, 25(10), 2203-2208.
- Kane, J. P., Malloy, M. J., Ports, T. A., Phillips, N. R., Diehl, J. C., & Havel, R. J. (1990). Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. *JAMA*, 264(23), 3007-3012.
- Katan, M. B., Grundy, S. M., Jones, P., Law, M., Miettinen, T., & Paoletti, R. (2003). Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. *Mayo Clin Proc*, 78(8), 965-978.

- Khanchadurian, A. K., & Uthman, S. M. (1973). Experiences with the homozygous cases of familial hypercholesterolaemia: a report of 52 patients. *Nutr Metab*, 15, 132-140.
- Khanchadurian, A. K. (1964). The inheritance of essential familial hypercholesterolaemia. *Am J Med*, 37, 402-407.
- Khoo, K. L., van Acker, P., Defesche, J. C., Tan, H., van de Kerkhof, L., Heijnen-van Eijk, S. J., et al. (2000). Low-density lipoprotein receptor gene mutations in a Southeast Asian population with familial hypercholesterolemia. *Clin Genet*, 58(2), 98-105.
- Khorram Khorshid, H. R., & Dalglish, R. (2008). The comparison of the effectiveness of a modified conformation sensitive gel electrophoresis with denaturing high performance liquid chromatography. *Iran Biomed J*, 12(2), 109-114.
- Khot, U. N., Khot, M. B., Bajzer, C. T., Sapp, S. K., Ohman, E. M., Brener, S. J., et al. (2003). Prevalence of conventional risk factors in patients with coronary heart disease. *JAMA*, 290(7), 898-904.
- Knott, T.J., Rall Jr., S.C., Innerarity, T.L., Jacobson, S.F., Urdea, M.S., Levy-Wilson, B., Powell, L.M., Pease, R.J., Eddy, R., Nakai, H., et al. (1985). Human apolipoprotein B: structure of carboxyl-terminal domains, sites of gene expression, and chromosomal localization. *Science*, 230 (4721), 37-43.
- Koivisto, P. V., Koivisto, U. M., Miettinen, T. A., & Kontula, K. (1992). Diagnosis of heterozygous familial hypercholesterolemia. DNA analysis complements clinical examination and analysis of serum lipid levels. *Arterioscler Thromb*, 12(5), 584-592.
- Koivisto, U. M., Hamalainen, L., Taskinen, M. R., Kettunen, K., & Kontula, K. (1993). Prevalence of familial hypercholesterolemia among young north Karelian patients with coronary heart disease: a study based on diagnosis by polymerase chain reaction. *J Lipid Res*, 34(2), 269-277.
- Koivisto, U. M., Turtola, H., Aalto-Setälä, K., Top, B., Frants, R. R., Kovanen, P. T., et al. (1992). The familial hypercholesterolemia (FH)-North Karelia mutation of the low density lipoprotein receptor gene deletes seven nucleotides of exon 6 and is a common cause of FH in Finland. *J Clin Invest*, 90(1), 219-228.
- Kolansky, D. M., Cuchel, M., Clark, B. J., Paridon, S., McCrindle, B. W., Wiegers, S. E., et al. (2008). Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia. *Am J Cardiol*, 102(11), 1438-1443.
- Kong, W. J., Liu, J., & Jiang, J. D. (2006). Human low-density lipoprotein receptor gene and its regulation. *J Mol Med*, 84(1), 29-36.
- Kotze, M. J., Langenhoven, E., Warnich, L., du Plessis, L., & Retief, A. E. (1991). The molecular basis and diagnosis of familial hypercholesterolaemia in South African Afrikaners. *Ann Hum Genet*, 55(Pt 2), 115-121.

- Kruth, H. S. (1985). Lipid deposition in human tendon xanthoma. *Am J Pathol*, 121(2), 311-315.
- Kwiterovich, P. O., Jr. (2000). The metabolic pathways of high-density lipoprotein, low-density lipoprotein, and triglycerides: a current review. *Am J Cardiol*, 86(12A), 5L-10L.
- Lagor, W.R., & Millar, J.S. (2010). Overview of the LDL receptor: relevance to cholesterol metabolism and future approaches for the treatment of coronary heart disease. *J Receptor Ligand Channel Res*, 3, 1-14.
- Lam, C. W. (2006). Analysis of polymerase chain reaction products by denaturing high-performance liquid chromatography. *Methods Mol Biol*, 336, 73-82.
- Landsberger, D., Meiner, V., Reshef, A., Levy, Y., van der Westhuyzen, D. R., Coetzee, G. A., et al. (1992). A nonsense mutation in the LDL receptor gene leads to familial hypercholesterolemia in the Druze sect. *Am J Hum Genet*, 50(2), 427-433.
- Law, S. W., Lee, N., Monge, J. C., Brewer, H. B., Jr., Sakaguchi, A. Y., & Naylor, S. L. (1985b). Human ApoB-100 gene resides in the p23----pter region of chromosome 2. *Biochem Biophys Res Commun*, 131(2), 1003-1012.
- Law, S.W., Lackner, K.J., Hospattankar, A.V., Anchors, J.M., Sakaguchi, A.Y., Naylor, S.L. and Brewer Jr., H.B. (1985a) Human apolipoprotein B-100: cloning, analysis of liver mRNA, and assignment of the gene to chromosome 2. *Proc Natl Acad Sci U S A*, 82, 8340–8344.
- Leeders, S., Raymond, S., Greenberg, H., Liu, H., and Esson, K. (2004). *A race against time: The challenge of cardiovascular disease in developing economies*. New York: Columbia University.
- Lehrman, M. A., Schneider, W. J., Brown, M. S., Davis, C. G., Elhammer, A., Russell, D. W., et al. (1987). The Lebanese allele at the low density lipoprotein receptor locus. Nonsense mutation produces truncated receptor that is retained in endoplasmic reticulum. *J Biol Chem*, 262(1), 401-410.
- Lehrman, M. A., Schneider, W. J., Sudhof, T. C., Brown, M. S., Goldstein, J. L., & Russell, D. W. (1985). Mutation in LDL receptor: Alu-Alu recombination deletes exons encoding transmembrane and cytoplasmic domains. *Science*, 227(4683), 140-146.
- Leigh, S.E.A., Foster, A.H., Whittall, C.S., Humpries, S.E. (2008). Update and analysis of the University College London low density lipoprotein receptor familial hypercholesterolaemia database. *Ann Hum Genet*, 72, 485-498.
- Leitersdorf, E. (2001). Cholesterol absorption inhibition: filling an unmet need in lipid-lowering management. *Eur Heart J*, 3 (Supp E), E17–E23.

- Leitersdorf, E. (2002). Selective cholesterol absorption inhibition: a novel strategy in lipid-lowering management. *Int J Clin Pract*, 56(2), 116-119.
- Leitersdorf, E., Tobin, E. J., Davignon, J., & Hobbs, H. H. (1990). Common low-density lipoprotein receptor mutations in the French Canadian population. *J Clin Invest*, 85(4), 1014-1023.
- Leung, K.H., & Yip, S.P. (2008). *Molecular Biomechanics Handbook. Denaturing high-performance liquid chromatography for nucleic acid analysis*. 2nd Edition. New Jersey: Humana Press Inc.
- Levy, E., Spahis, S., Sinnott, D., Peretti, N., Maupas-Schwalm, F., Delvin, E., et al. (2007). Intestinal cholesterol transport proteins: an update and beyond. *Curr Opin Lipidol*, 18(3), 310-318.
- Lewington, S., Whitlock, G., Clarke, R., Sherliker, P., Emberson, J., Halsey, J., et al. (2007). Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. *Lancet*, 370(9602), 1829-1839.
- Lichtenstein, A. H., Appel, L. J., Brands, M., Carnethon, M., Daniels, S., Franch, H. A., et al. (2006). Summary of American Heart Association Diet and Lifestyle Recommendations revision 2006. *Arterioscler Thromb Vasc Biol*, 26(10), 2186-2191.
- Lin, B., Madan, A., Yoon, J. G., Fang, X., Yan, X., Kim, T. K., et al. (2010). Massively parallel signature sequencing and bioinformatics analysis identifies up-regulation of TGFBI and SOX4 in human glioblastoma. *PLoS One*, 5(4), e10210.
- Lindgren, V., Luskey, K. L., Russell, D. W., & Francke, U. (1985). Human genes involved in cholesterol metabolism: chromosomal mapping of the loci for the low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl-coenzyme A reductase with cDNA probes. *Proc Natl Acad Sci U S A*, 82(24), 8567-8571.
- Live, O. (1999). An update on familial hypercholesterolaemia. *Ann Med*, 31(1), 13-18.
- Lo, Y.M.D., Chiu, R.W.K., & Chan, K.C.A. (2006). *Clinical applications of PCR*. 2nd edition. New Jersey: Humana Press Inc.
- Lombardi, P., Sijbrands, E. J., van de Giessen, K., Smelt, A. H., Kastelein, J. J., Frants, R. R., et al. (1995). Mutations in the low density lipoprotein receptor gene of familial hypercholesterolemic patients detected by denaturing gradient gel electrophoresis and direct sequencing. *J Lipid Res*, 36(4), 860-867.
- Lopez, A. D., Mathers, C. D., Ezzati, M., Jamison, D. T., & Murray, C. J. L. (2006). Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. *Lancet*, 367(9524), 1747-1757.

- Loria, C. M., Liu, K., Lewis, C. E., Hulley, S. B., Sidney, S., Schreiner, P. J., et al. (2007). Early adult risk factor levels and subsequent coronary artery calcification: the CARDIA Study. *J Am Coll Cardiol*, 49(20), 2013-2020.
- Marks, D., Thorogood, M., Neil, H. A. W., & Humphries, S. E. (2003). A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. *Atherosclerosis*, 168(1), 1-14.
- Marks, D., Wonderling, D., Thorogood, M., Lambert, H., Humphries, S. E., & Neil, H. A. (2000). Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis. *Health Technol Assess*, 4(29), 1-123.
- Marsh, D.J., & Howell, V.M. (2010). The use of denaturing high performance liquid chromatography (DHPLC) for mutation scanning of hereditary cancer genes. *Cancer susceptibility: methods and protocols*. New York: Springer Science Business Media.
- Marshall, J.W. (2000). *Clinical Chemistry*. Edinburgh: Elsevier Science.
- Mashal, R. D., & Sklar, J. (1996). Practical methods of mutation detection. *Curr Opin Genet Dev*, 6(3), 275-280.
- Matsuzaki, M., Hiramori, K., Imaizumi, T., Kitabatake, A., Hishida, H., Nomura, M., et al. (2002). Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART). *J Am Coll Cardiol*, 40(2), 220-227.
- Meiner, V., Landsberger, D., Berkman, N., Reshef, A., Segal, P., Seftel, H. C., et al. (1991). A common Lithuanian mutation causing familial hypercholesterolemia in Ashkenazi Jews. *Am J Hum Genet*, 49(2), 443-449.
- Minhas, R., Humphries, S. E., Qureshi, N., & Neil, H. A. (2009). Controversies in familial hypercholesterolaemia: recommendations of the NICE Guideline Development Group for the identification and management of familial hypercholesterolaemia. *Heart*, 95(7), 584-587; discussion 587-591.
- Mitchell, M., & Cutler, J. (2011). Denaturing HPLC for mutation screening. *Method Mol Biol*, 688, 17-33.
- Müller, C. (1938). Xanthomata, hypercholesterolemia, angina pectoris. *Acta Med Scand*, 89, 75-84.
- Muller, P.Y. and Miserez, A.R. (2002). Identification of mutations in the gene encoding sterol regulatory element binding protein (SREBP)-2 in hypercholesterolaemic subjects. *J Med Genet*, 39, 271-275.
- Murray, C.J.L and Lopez, A.D. (1996). *The global burden of disease*. Boston: Harvard School of Public Health.

- Murray, C.J.L, and Lopez, A.D. (1997). Mortality by cause for eight regions of the world: global burden of disease study. *Lancet*, 349, 1269-1276.
- National Institute for Health and Clinical Excellence. (2008). Clinical guidelines and evidence review for familial hypercholesterolaemia: the identification and management of adults and children with familial hypercholesterolaemia. Retrieved on December 10th, 2009, from www.nice.org.uk/CG71.
- Nawawi, H. M., Nor, I. M., Noor, I. M., Karim, N. A., Arshad, F., Khan, R., et al. (2002). Current status of coronary risk factors among rural Malays in Malaysia. *J Cardiovasc Risk*, 9(1), 17-23.
- Nissen, H., Hansen, A. B., & Jensen, H. K. (1995). A frequent HhaI polymorphism in intron 9 of the low density lipoprotein receptor gene detected by the denaturing gradient gel electrophoresis technique. *Clin Genet*, 48(4), 221-222.
- Nyren, P. (2006). The history of pyrosequencing. In Walker, J.M & Marsh, S. *Methods in molecular Biology: pyrosequencing protocols*. New Jersey: Humana Press Inc.
- Oefner, P. J. (2000). Allelic discrimination by denaturing high-performance liquid chromatography. *J Chromatogr B Biomed Sci Appl*, 739(2), 345-355.
- Oefner, P. J., & Huber, C. G. (2002). A decade of high-resolution liquid chromatography of nucleic acids on styrene-divinylbenzene copolymers. *J Chromatogr B Analyt Technol Biomed Life Sci*, 782(1-2), 27-55.
- Oefner, P.J, & Underhill, P.A (1999). DNA mutation detection using denaturing high – performance liquid chromatography. In: Dracopoli, N.C., Haines, J., Korf, B.R., et al, eds. *Current Protocols in Human Genetic*. New York: Wiley.
- Oefner, P.J., & Underhill, P.A. (1995) Comparative DNA sequencing by denaturing high-performance liquid chromatography (DHPLC). *Am. J. Hum. Genet.* 57 [Suppl.], A266.
- Ophoff, R. A., Terwindt, G. M., Vergouwe, M. N., van Eijk, R., Oefner, P. J., Hoffman, S. M., et al. (1996). Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca²⁺ channel gene CACNL1A4. *Cell*, 87(3), 543-552.
- Ose, L. (2002). Familial hypercholesterolemia from children to adults. *Cardiovasc Drugs Ther*, 16(4), 289-293.
- Park, J. W., Merz, M., & Braun, P. (1998). Effect of HELP-LDL-apheresis on outcomes in patients with advanced coronary atherosclerosis and severe hypercholesterolemia. *Atherosclerosis*, 139(2), 401-409.
- Patterson, D., and Slack, J. (1972). Lipid abnormalities in male and female survivors of myocardial infarction and their first-degree relatives. *Lancet*, 1, 393-399.

- Pedersen, T. R., Berg, K., Cook, T. J., Faergeman, O., Haghfelt, T., Kjekshus, J., et al. (1996). Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. *Arch Intern Med*, *156*(18), 2085-2092.
- Pfeiffer, R. M., Bura, E., Smith, A., & Rutter, J. L. (2002). Two approaches to mutation detection based on functional data. *Stat Med*, *21*(22), 3447-3464.
- Pullinger, C.R., Eng, C., Salen, G., Shefer, S., Batta, A.K., Erickson, S.K., Verhagen, A., Rivera, C.R., Mulvihill, S.J., Malloy, M.J., and Kane, J.P. (2002). Human cholesterol 7 α -hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. *J Clin Invest*, *110*, 109-117.
- Rader, D. J., Cohen, J., & Hobbs, H. H. (2003). Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. *J Clin Invest*, *111*(12), 1795-1803.
- Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). (1994). *Lancet*, *344*(8934), 1383-1389.
- Reinartz, J., Bruyns, E., Lin, J. Z., Burcham, T., Brenner, S., Bowen, B., et al. (2002). Massively parallel signature sequencing (MPSS) as a tool for in-depth quantitative gene expression profiling in all organisms. *Brief Funct Genomic Proteomic*, *1*(1), 95-104.
- Reshef, A., Nissen, H., Triger, L., Hensen, T. S., Eliav, O., Schurr, D., et al. (1996). Molecular genetics of familial hypercholesterolemia in Israel. *Hum Genet*, *98*(5), 581-586.
- Romano, M., Di Taranto, M. D., D'Agostino, M. N., Marotta, G., Gentile, M., Abate, G., et al. (2010). Identification and functional characterization of LDLR mutations in familial hypercholesterolemia patients from Southern Italy. *Atherosclerosis*, *210*(2), 493-496.
- Rossiter, B. J., & Caskey, C. T. (1990). Molecular scanning methods of mutation detection. *J Biol Chem*, *265*(22), 12753-12756.
- Rubba, P., Marotta, G., & Gentile, M. (2009). Efficacy and safety of rosuvastatin in the management of dyslipidemia. *Vasc Health Risk Manag*, *5*(1), 343-352.
- Rugg, E.L., & Magee, G.J. (2005). *Medical Biomethods Handbook. Use of denaturing high-performance liquid chromatography in molecular medicine*. New Jersey: Humana Press Inc.
- Russell, D. W., Lehrman, M. A., Sudhof, T. C., Yamamoto, T., Davis, C. G., Hobbs, H. H., et al. (1986). The LDL receptor in familial hypercholesterolemia: use of human mutations to dissect a membrane protein. *Cold Spring Harb Symp Quant Biol*, *51 Pt 2*, 811-819.

- Russell, D. W., Schneider, W. J., Yamamoto, T., Luskey, K. L., Brown, M. S., & Goldstein, J. L. (1984). Domain map of the LDL receptor: sequence homology with the epidermal growth factor precursor. *Cell*, 37(2), 577-585.
- Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., et al. (1996). The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. *N Engl J Med*, 335(14), 1001-1009.
- Sambrook, J., Fritsch, E. F. and Maniatis, T. (1989) *Molecular cloning: a laboratory manual*. New York: Cold Spring Harbor Laboratory Press.
- Scientific Steering Committee on behalf of the Simon Broome Register Group. (1991). Risk of fatal coronary heart disease in familial hypercholesterolaemia. *BMJ*, 303(6807), 893-896.
- Scientific Steering Committee on behalf of the Simon Broome Register Group. (1999). Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. *Atherosclerosis*, 142(1), 105-112.
- Serruys, P. W., de Feyter, P., Macaya, C., Kokott, N., Puel, J., Vrolix, M., et al. (2002). Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. *JAMA*, 287(24), 3215-3222.
- Sever, P. S., Dahlof, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., et al. (2003). Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. *Lancet*, 361(9364), 1149-1158.
- Shendure, J., Porreca, G. J., Reppas, N. B., Lin, X., McCutcheon, J. P., Rosenbaum, A. M., et al. (2005). Accurate multiplex polony sequencing of an evolved bacterial genome. *Science*, 309(5741), 1728-1732.
- Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., MacFarlane, P. W., et al. (1995). Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. *N Engl J Med*, 333(20), 1301-1307.
- Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., MacFarlane, P. W., et al. (1995). Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. *N Engl J Med*, 333(20), 1301-1307.
- Shi, M. M. (2001). Enabling large-scale pharmacogenetic studies by high-throughput mutation detection and genotyping technologies. *Clin Chem*, 47(2), 164-172.

- Sivakumaran, T.A., Kucheria, K., Oefner, P.J. (2003). Denaturing high performance liquid chromatography in the molecular diagnosis of genetic disorders. *Curr Sci*, 84(3), 291-296.
- Slack, J. (1969). Risks of ischaemic heart disease in familial hypercholesterolaemic states. *Lancet*, 2, 1380-1382.
- Slater, H. R., McKinney, L., Packard, C. J., & Shepherd, J. (1984). Contribution of the receptor pathway to low density lipoprotein catabolism in humans. New methods for quantitation. *Arteriosclerosis*, 4(6), 604-613.
- Smith, L. M., Sanders, J. Z., Kaiser, R. J., Hughes, P., Dodd, C., Connell, C. R., et al. (1986). Fluorescence detection in automated DNA sequence analysis. *Nature*, 321(6071), 674-679.
- Soutar, A. K. (1996). Intracellular transport of the low-density lipoprotein receptor. *Biochem Soc Trans*, 24(2), 547-552.
- Soutar, A. K., & Knight, B. L. (1990). Structure and regulation of the LDL-receptor and its gene. *Br Med Bull*, 46(4), 891-916.
- Soutar, A. K., & Naoumova, R. P. (2007). Mechanisms of disease: genetic causes of familial hypercholesterolemia. *Nat Clin Pract Cardiovasc Med*, 4(4), 214-225.
- Sozen, M., Whittall, R., & Humphries, S. E. (2004). Mutation detection in patients with familial hypercholesterolaemia using heteroduplex and single strand conformation polymorphism analysis by capillary electrophoresis. *Atheroscler Suppl*, 5(5), 7-11.
- Spady, D. K. (1992). Hepatic clearance of plasma low density lipoproteins. *Semin Liver Dis*, 12(4), 373-385.
- Stamler, J., Daviglius, M. L., Garside, D. B., Dyer, A. R., Greenland, P., & Neaton, J. D. (2000). Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. *JAMA*, 284(3), 311-318.
- Stein, E. A. (2002). Managing dyslipidemia in the high-risk patient. *Am J Cardiol*, 89(5A), 50C-57C.
- Steinberg, D. (2006a). Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part V: the discovery of the statins and the end of the controversy. *J Lipid Res*, 47(7), 1339-1351.
- Steinberg, D. (2006b). The pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part IV: the 1984 coronary primary prevention trial ends it--almost. *J Lipid Res*, 47(1), 1-14.
- Stenson, P. D., Ball, E. V., Howells, K., Phillips, A. D., Mort, M., & Cooper, D. N. (2009a). The Human Gene Mutation Database: providing a comprehensive

central mutation database for molecular diagnostics and personalized genomics. *Hum Genomics*, 4(2), 69-72.

Stenson, P. D., Ball, E. V., Mort, M., Phillips, A. D., Shiel, J. A., Thomas, N. S., et al. (2003). Human Gene Mutation Database (HGMD): 2003 update. *Hum Mutat*, 21(6), 577-581.

Stenson, P. D., Ball, E., Howells, K., Phillips, A., Mort, M., & Cooper, D. N. (2008). Human Gene Mutation Database: towards a comprehensive central mutation database. *J Med Genet*, 45(2), 124-126.

Stenson, P. D., Mort, M., Ball, E. V., Howells, K., Phillips, A. D., Thomas, N. S., et al. (2009b). The Human Gene Mutation Database: 2008 update. *Genome Med*, 1(1), 13.

Stone, N.J., Levy, R.I., Fredrickson, D.S., and Verter, J. (1974). Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. *Circulation*, 49, 476-488.

Sudhof, T. C., Goldstein, J. L., Brown, M. S., & Russell, D. W. (1985). The LDL receptor gene: a mosaic of exons shared with different proteins. *Science*, 228(4701), 815-822.

Taylor, A., Wang, D., Patel, K., Whittall, R., Wood, G., Farrer, M., et al. (2010). Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project. *Clin Genet*, 77(6), 572-580.

Taylor, C. F., & Taylor, G. R. (2004). Current and emerging techniques for diagnostic mutation detection: an overview of methods for mutation detection. *Methods Mol Med*, 92, 9-44.

Taylor, G.R. (1997). *Laboratory methods for the detection of mutations and polymorphisms in DNA*. Boca Raton: CRC Press.

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. (2002). *Circulation*, 106(25), 3143-3421.

Thompson, G. R. (2003). LDL apheresis. *Atherosclerosis*, 167(1), 1-13.

Thorogood, M., Betteridge, D.J., Broome, K., Durrington, P.N., Mann, J.I., Miller, J.P., Neil, H.A.W., and Thompson, G.R. (1991). Risk of fatal coronary heart disease in familial hypercholesterolaemia: Scientific Steering Committee on behalf of the Simon Broome Register Group. *Brit Med J*, 303, 893-896.

Tobert, J. A. (2003). Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. *Nat Rev Drug Discov*, 2(7), 517-526.

- Tybjaerg-Hansen, A., & Humphries, S. E. (1992). Familial defective apolipoprotein B-100: a single mutation that causes hypercholesterolemia and premature coronary artery disease. *Atherosclerosis*, *96*(2-3), 91-107.
- Umans-Eckenhausen, M. A., Defesche, J. C., Sijbrands, E. J., Scheerder, R. L., & Kastelein, J. J. (2001). Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. *Lancet*, *357*(9251), 165-168.
- Umans-Eckenhausen, M. A., Defesche, J. C., van Dam, M. J., & Kastelein, J. J. (2003). Long-term compliance with lipid-lowering medication after genetic screening for familial hypercholesterolemia. *Arch Intern Med*, *163*(1), 65-68.
- Underhill, P. A., Shen, P., Lin, A. A., Jin, L., Passarino, G., Yang, W. H., et al. (2000). Y chromosome sequence variation and the history of human populations. *Nat Genet*, *26*(3), 358-361.
- US Food and Drug administration. FDA authorize new coronary heart disease health claim for plant sterol and plant stanol esters. Retrieved on August 24th, 2010 from <http://www.fda.gov/ohrms/dockets/DOCKETS/95s0316/95s-0316-Rpt0272-39-Appendix-D-Reference-F-FDA-vol205.pdf>.
- Vago, A.R., & Pena, S.D.J. (1997). Laboratory techniques for the detection of mutations in DNA. *Braz J Genet*, *20* (2), 339-344.
- van Aalst-Cohen, E. S., Jansen, A. C., Tanck, M. W., Defesche, J. C., Trip, M. D., Lansberg, P. J., et al. (2006). Diagnosing familial hypercholesterolaemia: the relevance of genetic testing. *Eur Heart J*, *27*(18), 2240-2246.
- van der Graaf, A., Kastelein, J. J. P. (2009). Heterozygous familial hypercholesterolaemia in childhood: cardiovascular risk prevention. *J Inherit Metab Dis*, *32*, 699-705.
- van der Westhuyzen, D. R., Stein, M. L., Henderson, H. E., Marais, A. D., Fourie, A. M., & Coetzee, G. A. (1991). Deletion of two growth-factor repeats from the low-density-lipoprotein receptor accelerates its degradation. *Biochem J*, *277* (Pt 3), 677-682.
- van der Westhuyzen, D. R., Stein, M. L., Henderson, H. E., Marais, A. D., Fourie, A. M., & Coetzee, G. A. (1991). Deletion of two growth-factor repeats from the low-density-lipoprotein receptor accelerates its degradation. *Biochem J*, *277* (Pt 3), 677-682.
- van Pelt-Verkuil, E., van Belkum, A., & Hays, J.P. (2007). *Principles and technical aspects of PCR amplification*. New Jersey: Humana Press Inc.
- Varret, M., Abifadel, M., Rabes, J. P., & Boileau, C. (2008). Genetic heterogeneity of autosomal dominant hypercholesterolemia. *Clin Genet*, *73*(1), 1-13.
- Varret, M., Rabes, J. P., Collod-Beroud, G., Junien, C., Boileau, C., & Beroud, C. (1997). Software and database for the analysis of mutations in the human LDL receptor gene. *Nucleic Acids Res*, *25*(1), 172-180.

- Varret, M., Rabes, J. P., Saint-Jore, B., Cenarro, A., Marinoni, J. C., Civeira, F., et al. (1999). A third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1-p32. *Am J Hum Genet*, *64*(5), 1378-1387.
- Vega, G. L., & Grundy, S. M. (1987). Mechanisms of primary hypercholesterolemia in humans. *Am Heart J*, *113*(2 Pt 2), 493-502.
- Vega, G. L., Denke, M. A., & Grundy, S. M. (1991). Metabolic basis of primary hypercholesterolemia. *Circulation*, *84*(1), 118-128.
- Villegier, L., Abifadel, M., Allard, D., Rabes, J. P., Thiart, R., Kotze, M. J., et al. (2002). The UMD-LDLR database: additions to the software and 490 new entries to the database. *Hum Mutat*, *20*(2), 81-87.
- Vogel, F., & Motulsky, A.G. (1986). *Human genetics: problems and approaches*. 2nd edition. New York: Springer-Verlag.
- Vogel, R. A. (1998). The management of hypercholesterolemia in patients with coronary artery disease: guidelines for primary care. *Clin Cornerstone*, *1*(1), 51-64.
- Wallace, R. B., Shaffer, J., Murphy, R. F., Bonner, J., Hirose, T., & Itakura, K. (1979). Hybridization of synthetic oligodeoxyribonucleotides to phi chi 174 DNA: the effect of single base pair mismatch. *Nucleic Acids Res*, *6*(11), 3543-3557.
- Ward, A. J., O'Kane, M., Nicholls, D. P., Young, I. S., Nevin, N. C., & Graham, C. A. (1996). A novel single base deletion in the LDLR gene (211delG): Effect on serum lipid profiles and the influence of other genetic polymorphisms in the ACE, APOE and APOB genes. *Atherosclerosis*, *120*(1-2), 83-91.
- Watts, G. F., Hamilton-Craig, I., & Sullivan, D. R. (2009). NICE guidance on familial hypercholesterolaemia: all sugar and spice? *Heart Lung Circ*, *18*(3), 181-183.
- Weingartner, O., Bohm, M., & Laufs, U. (2009). Controversial role of plant sterol esters in the management of hypercholesterolaemia. *Eur Heart J*, *30*(4), 404-409.
- Williams, R. R., Hasstedt, S. J., Wilson, D. E., Ash, K. O., Yanowitz, F. F., Reiber, G. E., et al. (1986). Evidence that men with familial hypercholesterolemia can avoid early coronary death. An analysis of 77 gene carriers in four Utah pedigrees. *JAMA*, *255*(2), 219-224.
- Williams, R. R., Hunt, S. C., Schumacher, M. C., Hegele, R. A., Leppert, M. F., Ludwig, E. H., et al. (1993). Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. *Am J Cardiol*, *72*(2), 171-176.
- World Health Organisation. (1995). *WHO Technical Report Series: Physical Status. The use and interpretation of anthropometry*. Retrieved on January 6, 2010, from http://whqlibdoc.who.int/trs/WHO_TRS_854.pdf.

- World Health Organisation. (1999). Familial hypercholesterolaemia- report of a second WHO Consultation. Geneva: WHO Publication. Retrieved on June 12th, 2008, from whqlibdoc.who.int/hq/1999/WHO_HGN_FH_CONS_99.2.pdf.
- World Health Organisation. (2002). Factsheet on cardiovascular diseases. Retrieved on July 26, 2010, from <http://www.who.int/mediacentre/factsheet/fs317/en/index.html>
- World Health Organisation. (2002). The impact of chronic heart disease in Malaysia. Retrieved on July 26th, 2010, from http://www.who.int/chp/chronic_disease_report/media/impact/malaysia.pdf.
- Xiao, W., & Oefner, P. J. (2001). Denaturing high-performance liquid chromatography: A review. *Hum Mutat*, 17(6), 439-474.
- Yamamoto, A., Kamiya, T., Yamamura, T., Yokoyama, S., Horiguchi, Y., Funahashi, T., et al. (1989). Clinical features of familial hypercholesterolemia. *Arteriosclerosis*, 9(1 Suppl), I66-74.
- Yamamoto, T., Davis, C. G., Brown, M. S., Schneider, W. J., Casey, M. L., Goldstein, J. L., et al. (1984). The human LDL receptor: a cysteine-rich protein with multiple Alu sequences in its mRNA. *Cell*, 39(1), 27-38.
- Yamanoshita, O., Kubota, T., Hou, J., Ping, Y. M., Zhang, X. L., Li, X. P., et al. (2005). DHPLC is superior to SSCP in screening p53 mutations in esophageal cancer tissues. *Int J Cancer*, 114(1), 74-79.
- Yuan, G., Wang, J., & Hegele, R. A. (2006). Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease. *CMAJ*, 174(8), 1124-1129.
- Zambahari, R. (2004). Trends in cardiovascular disease and risk factors in Malaysia. *Int Congr Ser*, 1262, 446-449.